A photo of Cuixia Tian.

Neuromuscular Disease Specialist, Division of Neurology

Assistant Professor, UC Department of Pediatrics


Board Certified

Make an Appointment

"I believe in wholistic healthcare, which allows me to assess and care for patients using a systemic approach. Wholistic care helps me fully understand my patients’ diseases along with the obstacles they face, and this helps me deliver the best care to meet their needs."

About Me


Since childhood, I was fascinated with medicine and wanted to become a doctor. I love children, and during medical school, I decided I wanted to become a pediatrician. I was drawn to pediatric neurology during my residency training and became a board-certified pediatric neurologist. I am passionate about taking care of children with neurological diseases and consider this a privilege.

As a child neurologist, I work with children and adolescents with neurological diseases, especially neuromuscular conditions. I believe in wholistic healthcare, which allows me to assess and care for patients using a systemic approach. Wholistic care helps me fully understand my patients’ diseases along with the obstacles they face, and this helps me deliver the best care to meet their needs.

I am the director of the Muscular Dystrophy Association Clinic, the Parent Project for Muscular Dystrophy and the Certified Duchenne Muscular Dystrophy Care Clinic. I am co-director of Cincinnati Children’s Comprehensive Neuromuscular Center. Our clinic offers multidisciplinary care from providers in the areas of neurology, cardiology, pulmonology, physical therapy, psychology, nutrition, genetics, rehabilitation medicine and orthopaedics.

My clinical research focuses on new drug development for patients with pediatric neuromuscular diseases. I am determined to conduct medical research to find better treatments for our patients. I am the principal investigator for several industry-sponsored clinical studies and coinvestigator for National Institutes of Health-sponsored research. In these clinical studies, my colleagues and I are investigating the efficacy and safety of new drugs for treating patients with pediatric neuromuscular diseases and molecular mechanisms underlying the disease process. We are studying diseases such as Duchenne muscular dystrophy, spinal muscular atrophy and myotonic dystrophy.

In my free time, I enjoy gardening, going to the park, listening to music, and playing badminton and tennis with my family.

Additional Languages


Academic Affiliation

Assistant Professor, UC Department of Pediatrics

My Locations

My Education

MD: Medical Center of Fudan University, Shanghai, China, 1993.

Residency: Cincinnati Children’s Hospital Medical Center.

Myology Institute Clinical Myology Training; Paris, France, 2014.

Wellstone Myology Training; Ohio State University, Columbus, OH, 2013.

World Muscle Society Satellite Training; Asilomar, California, 2013.

My Publications

A Randomized, Double-Blind, Placebo-Controlled, Global Phase 3 Study of Edasalonexent in Pediatric Patients with Duchenne Muscular Dystrophy: Results of the PolarisDMD Trial. Finkel, RS; McDonald, CM; Lee Sweeney, H; Finanger, E; Neil Knierbein, E; Wagner, KR; Mathews, KD; Marks, W; Statland, J; Nance, J; et al. Journal of Neuromuscular Diseases. 2021; 8:769-784.

Treatment of SCN4A-induced myotonic crisis. Ritter, DM; Tian, C; Broomall, E. Muscle and Nerve. 2021; 63:E59-E61.

An autosomal dominant neurological disorder caused by de novo variants in FAR1 resulting in uncontrolled synthesis of ether lipids. Ferdinandusse, S; McWalter, K; te Brinke, H; IJlst, L; Mooijer, PM; Ruiter, JP N; van Lint, AE M; Pras-Raves, M; Wever, E; Millan, F; et al. Genetics in Medicine. 2021; 23:740-750.

Age-related changes in appendicular lean mass in males with Duchenne muscular dystrophy: A retrospective review. Summer, SS; Wong, BL; Rutter, MM; Horn, PS; Tian, C; Rybalsky, I; Shellenbarger, KC; Kalkwarf, HJ. Muscle and Nerve. 2021; 63:231-238.

Safety and efficacy of teriparatide treatment for severe osteoporosis in patients with Duchenne muscular dystrophy. Nasomyont, N; Keefe, C; Tian, C; Hornung, L; Khoury, J; Tilden, JC; Hochwalt, P; Jackson, E; Rybalsky, I; Wong, BL; et al. Osteoporosis International. 2020; 31:2449-2459.

Oral bisphosphonate treatment in patients with Duchenne muscular dystrophy on long term glucocorticoid therapy. Tian, C; Wong, BL; Hornung, L; Khoury, JC; Rybalsky, I; Shellenbarger, KC; Rutter, MM. Neuromuscular Disorders. 2020; 30:599-610.

Randomized phase 2 trial and open-label extension of domagrozumab in Duchenne muscular dystrophy. Wagner, KR; Abdel-Hamid, HZ; Mah, JK; Campbell, C; Guglieri, M; Muntoni, F; Takeshima, Y; McDonald, CM; Kostera-Pruszczyk, A; Karachunski, P; et al. Neuromuscular Disorders. 2020; 30:492-502.

Neurodevelopmental, behavioral, and emotional symptoms common in Duchenne muscular dystrophy. Darmahkasih, AJ; Rybalsky, I; Tian, C; Shellenbarger, KC; Horn, PS; Lambert, JT; Wong, BL. Muscle and Nerve. 2020; 61:466-474.

MRI vastus lateralis fat fraction predicts loss of ambulation in Duchenne muscular dystrophy. Naarding, KJ; Reyngoudt, H; van Zwet, EW; Hooijmans, MT; Tian, C; Rybalsky, I; Shellenbarger, KC; Le Louer, J; Wong, BL; Carlier, PG; et al. Neurology. 2020; 94:e1386-e1394.

Real-world outcomes of long-term prednisone and deflazacort use in patients with Duchenne muscular dystrophy: experience at a single, large care center. Marden, JR; Freimark, J; Yao, Z; Signorovitch, J; Tian, C; Wong, BL. Journal of Comparative Effectiveness Research. 2020; 9:177-189.